drugset / Trial / NCT00969618

A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder

NCT00969618

Phase 3 Completed 211 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess long-term safety and tolerability in adult patients who have completed a previous atomoxetine study.

Timeline

Start
2009-11
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 40 mg Oral
Subject Atomoxetine Other / unclassified 120 mg Oral